Gaush Meditech Ltd
Gaush Meditech Ltd. engages in the research and development, production, and distribution of ophthalmic medical equipment and consumables, and the provision of technical services to end customers. The company's product portfolio comprising proprietary products, which it develops and manufactures, as well as distribution products of its brand partners, which it distributes, covering seven ophthalm… Read more
Gaush Meditech Ltd (F7Y) - Net Assets
Latest net assets as of June 2025: €1.68 Billion EUR
Based on the latest financial reports, Gaush Meditech Ltd (F7Y) has net assets worth €1.68 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.57 Billion) and total liabilities (€897.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.68 Billion |
| % of Total Assets | 65.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.28 |
Gaush Meditech Ltd - Net Assets Trend (2021–2024)
This chart illustrates how Gaush Meditech Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gaush Meditech Ltd (2021–2024)
The table below shows the annual net assets of Gaush Meditech Ltd from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.59 Billion | -6.41% |
| 2023-12-31 | €1.70 Billion | +14.15% |
| 2022-12-31 | €1.49 Billion | +334.73% |
| 2021-12-31 | €-633.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gaush Meditech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23225700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.04 Billion | 129.78% |
| Total Equity | €1.58 Billion | 100.00% |
Gaush Meditech Ltd Competitors by Market Cap
The table below lists competitors of Gaush Meditech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vranken-Pommery Monopole Société Anonyme
PA:VRAP
|
$29.55 Million |
|
PTT Synergy Group Bhd
KLSE:7010
|
$29.56 Million |
|
Hwang-Kum Stee
KO:032560
|
$29.56 Million |
|
SILVER CROWN ROYALTIES INC.
NEO:SCRI
|
$29.57 Million |
|
S Connect Co. LTD
KQ:096630
|
$29.53 Million |
|
ZUARI INDUSTRIES LIMITED
NSE:ZUARIIND
|
$29.53 Million |
|
NMC Resource Corporation
V:NRC
|
$29.53 Million |
|
TV Today Network Limited
NSE:TVTODAY
|
$29.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gaush Meditech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,680,467,000 to 1,575,139,000, a change of -105,328,000 (-6.3%).
- Net income of 92,394,000 contributed positively to equity growth.
- Share repurchases of 161,132,000 reduced equity.
- Other factors decreased equity by 36,590,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €92.39 Million | +5.87% |
| Share Repurchases | €161.13 Million | -10.23% |
| Other Changes | €-36.59 Million | -2.32% |
| Total Change | €- | -6.27% |
Book Value vs Market Value Analysis
This analysis compares Gaush Meditech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-4.44 | €0.58 | x |
| 2022-12-31 | €9.93 | €0.58 | x |
| 2023-12-31 | €11.36 | €0.58 | x |
| 2024-12-31 | €10.65 | €0.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gaush Meditech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.87%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.47%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.63x
- Recent ROE (5.87%) is above the historical average (-1.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -14.67% | 0.53x | 0.00x | €-124.80 Million |
| 2022 | -23.79% | -27.89% | 0.46x | 1.85x | €-496.57 Million |
| 2023 | 10.33% | 12.34% | 0.49x | 1.69x | €5.48 Million |
| 2024 | 5.87% | 6.47% | 0.56x | 1.63x | €-65.12 Million |
Industry Comparison
This section compares Gaush Meditech Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $92,586,437
- Average return on equity (ROE) among peers: -83.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gaush Meditech Ltd (F7Y) | €1.68 Billion | 0.00% | 0.54x | $29.55 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |